Cipher Pharmaceuticals earnings date
Want to see TSE:CPH full AI Analyst Report?
Cipher Pharmaceuticals (CPH) Q3 2026 Earnings Report
TSE:CPH Q3 2026 EPS Results
- Actual EPS
- CAD 0.60
- Consensus EPS
- CAD 0.30
- Beat/Miss
- Beat by +CAD 0.30
- One Year Ago EPS
- CAD 0.30
TSE:CPH Q3 2026 Revenue Results
- Actual Revenue
- CAD 17.78M
- Expected Revenue
- CAD 18.79M
- Beat/Miss
- Missed by -CAD 1.01M
- YoY Revenue Growth
- +0.60%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- After Close
- Conference Call
- Thursday, November 12, 2026
Cipher Pharmaceuticals's next earnings date is estimated for March 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive, supported by strong profitability, cash generation, debt-free status, the favorable arbitration ruling, Epuris growth, expanded Canadian reimbursement and active business development efforts. However, revenue and product sales declined year over year, Natroba continues to face Medicaid-related pressure, arbitration benefits were nonrecurring, and a previously advanced acquisition did not close. The highlights significantly outweighed the lowlights.
Cipher expects the Health Canada review of Natroba for head lice and scabies to be completed “soon and likely in the first quarter of 2027,” expects expanded Epuris public coverage to “continue contributing to market share growth over time,” and said the 15% royalty on net sales of Absorica LD in Canada runs “through 2040”; with approximately $20 million of cash post quarter end, $65 million of undrawn availability on its facility, a $25 million accordion feature subject to lender approval, and continued positive operating cash flows, the company said it is positioned to continue investing in its growth strategy, remains optimistic about finding the right opportunity, expects “that we get something done in the short term,” and considers expanding the US business a priority while also looking at opportunities in Canada.
- Strong Profitability and Adjusted EBITDA MarginThird-quarter net income was $10.9 million, or $0.42 per diluted share, and adjusted EBITDA was $7.2 million with a 57% margin. Year-to-date adjusted EBITDA increased 3% to $21.8 million, while the adjusted EBITDA margin improved to 58% from 55%.
- Arbitration Award Confirmed in Cipher's FavorOn September 1, the New York Federal Court affirmed the arbitration award, including Cipher's ownership of the disputed clinical data, C$4.2 million in compensatory damages, a 15% royalty on net sales of Absorica LD in Canada, 80% of eligible out-of-pocket attorney's fees and expenses, and interest. Cipher received $5.7 million in October related to damages, fees, expenses and interest, and management reiterated a potential 15% royalty through 2040.
- Revenue Essentially In Line Despite Portfolio Mix PressuresThird-quarter net revenue was $12.7 million, essentially in line with the prior-year quarter, as Epuris growth and higher licensing revenue largely offset lower Natroba sales in the United States.
- Licensing Revenue Increased MateriallyThird-quarter licensing revenue increased 62% to $1.2 million, including a 75% increase in Absorica licensing revenue to $700,000 and a 67% increase in LipoFin and authorized-generic licensing revenue to $500,000. Year-to-date licensing revenue increased 17% to $3.5 million.
- Epuris Continued to Grow in CanadaCanadian product revenue increased 8% to $4.3 million in the third quarter. Epuris revenue increased 15% to $3.9 million for the quarter and increased 7% year to date to $11.9 million. Epuris reached 48.7% share of Canada's isotretinoin market as of September 30, 2026, up 1.6 percentage points from 47.1% in June.
- Expanded Public Reimbursement for EpurisCipher finalized the majority of additional product listing agreements following the pan-Canadian Pharmaceutical Alliance letter of intent. Public funding became effective in British Columbia on August 17, Quebec on August 27, and Alberta on October 1, with additional jurisdictions also listed.
- Natroba Showed Sequential ImprovementAlthough Natroba and its authorized generic generated $7.1 million in third-quarter revenue, down 12% year over year, revenue increased 14% sequentially from the second quarter, ahead of the 4% sequential increase during the same period last year.
- Investment in Expanding Natroba Beyond MedicaidCipher continued investing in commercial payer, direct-to-patient and retail pharmacy initiatives to expand the U.S. Natroba business beyond the Medicaid channel. The company also invested heavily in 2026 marketing to educate patients and prescribers about Natroba's effectiveness for head lice and scabies.
- Natroba International Opportunity and Out-Licensing InterestHealth Canada accepted Cipher's Natroba submission for review for head lice and scabies, with results expected soon and likely in the first quarter of 2027. Cipher also reported interest from parties in various markets for out-licensing Natroba, citing unmet need and the product's single-treatment positioning.
- Strong Gross MarginsThird-quarter gross margin was 82%, consistent with the prior-year quarter. Year-to-date gross margin increased to 81% from 80%, with the company attributing the increase largely to nonrecurring fair-value adjustments included in prior-year cost of products sold.
- Lower Operating Expenses and SG&ATotal operating expenses, net of arbitration-related income and recoveries, decreased 62% to $3.0 million in the third quarter and 32% to $17.5 million year to date. Third-quarter SG&A decreased 68% to $1.2 million, while year-to-date SG&A decreased 41% to $7.5 million, reflecting the arbitration-related legal-cost recovery, lower prior-year legal costs and operational efficiencies.
- Improved Cash Position and No DebtCipher ended the quarter with $15.3 million in cash, up from $9.1 million at the end of the second quarter, and collected an additional $5 million after quarter end, bringing cash to approximately $20 million. The company remains debt free and has $65 million of undrawn facility availability plus a $25 million accordion feature subject to lender approval.
- Business Development Activity Remains ActiveCipher continued pursuing complementary product acquisitions or in-licensing, out-licensing of Epuris and Natroba outside North America, and acquisitions of companies with strategic value. Management said it was assessing opportunities, holding vendor discussions and receiving additional interest in both products.
- Board Strengthened for M&A ExecutionCipher appointed Rajiv DeSilva to its board. He brings more than 30 years of healthcare experience and a track record in mergers and acquisitions. The board now has four members, three of whom are independent.
- Additional Support for Out-Licensing and Product SourcingCipher engaged a consulting firm with strategic business development expertise to support out-licensing efforts for Natroba and Epuris and to help identify product acquisition and in-licensing targets.
- Medicaid Renewal and Step-Through Discussions ContinueCipher continues pursuing Medicaid step-through arrangements at the state level. Management said utilization remains strong in states where coverage is renewed, and the company has had some uptake in discussions using Illinois as an example, although decisions vary by state.
- Potential Capital Deployment OptionsManagement said it may reduce NCIB purchases if a transaction is close and is considering a substantial issuer bid as a more effective way to repurchase shares because the NCIB is restrictive.
- U.S. Expansion Is a Priority for Future TransactionsManagement said expanding the U.S. business and increasing volume through its existing U.S. infrastructure is a priority, while also evaluating opportunities in Canada.
TSE:CPH Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 18, 2027 | 2026 (Q4) | 0.29- | 0.73 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | 0.300.60 | 0.3 | 100.00% (+0.30) | |
| Aug 11, 2026 | 2026 (Q2) | 0.290.21 | 0.31 | -31.82% (-0.10) | |
| May 07, 2026 | 2026 (Q1) | 0.190.34 | 0.14 | 140.00% (+0.20) | |
| Mar 12, 2026 | 2025 (Q4) | 0.220.73 | 0.19 | 292.31% (+0.54) | |
| Nov 06, 2025 | 2025 (Q3) | 0.210.30 | 0.01 | 2000.00% (+0.29) | |
| Aug 07, 2025 | 2025 (Q2) | 0.230.31 | 0.17 | 83.33% (+0.14) | |
| May 08, 2025 | 2025 (Q1) | 0.150.14 | 0.29 | -50.00% (-0.14) | |
| Mar 18, 2025 | 2024 (Q4) | 0.270.19 | 0.43 | -56.67% (-0.24) | |
| Nov 07, 2024 | 2024 (Q3) | 0.200.01 | 0.39 | -96.30% (-0.37) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


